Endocrine Abstracts

The aim: To evaluate the risk factors for symptomatic hypoglycemia (SG) over 4 years of intensive insulin treatment (IIT) and combined therapy (CT) in type 2 diabetes.

Material and methods: Under our supervision in the departments of the Center of Endocrinology of PH Ministry of RUz in the period from September 2016 for December, to 2017, 20 patients were observed with DM 2, men – 9, women – 11; 54.5±1.5 m/61.6±1.8 w years old. The remoteness of disease hesitated in limits from 7 to 9 years. All patients were observed by standard rules.

Results: Patients were distributed on two groups: 1 gr – 10 patients (5/5), which received IIT, 2 gr – 10 patients (4/6) on CT (insulin + Metformin, SM, etc). In 1st gr BMI 28.5±1.5/27.14±1.8, in 2 gr – BMI 36.6±1.4/31.6±1.2. For patients with DM 2 on IIT we found the duration of IIT – more than 3.6 years for men and 5 years for women. In second group the start of IIT – more than 3.75 years for men and 5.1 years for women. The middle range of HbA1C in 1st gr: 7.3±0.2 for men and 7.9±0.4 for women. The middle range of HbA1C in 2nd gr: 8.4±0.4 for men and 8.02±0.5 for women. Among comprehensive diseases we found in 1st gr: ischemic heart disease (IHD) 1/3, arterial hypertension (AH) 5/5, dislipidemiya (D) 0/1, liver cirrhosis 1/0, diabetic nephropathy (DN) II-III 5/2. In 2nd gr: IHD 0/4, AH 4/4, D 1/0, DN II-III 3/4.All patients have diabetic encephalopathy I-II

Conclusions: 1) For patients with DM 2 on IIT among risk factors of symptomatic hypoglycemia we found the AH and DN, for DM 2 on CT – AH, DN, BMI – 36.6±1.4/31.6±1.2 for men and women. 2) For patients with DM2 on ITT and CT among risk factors of symptomatic hypoglycemia we found diabetic encephalopathy I-II.